Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1995 Mar;54(3):197–200. doi: 10.1136/ard.54.3.197

Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

J J Belch 1, H A Capell 1, E D Cooke 1, J D Kirby 1, C S Lau 1, R Madhok 1, E Murphy 1, M Steinberg 1
PMCID: PMC1005556  PMID: 7538285

Abstract

OBJECTIVE--To compare the efficacy, tolerance and safety of 50-150 micrograms orally administered iloprost given twice a day versus placebo in patients with Raynaud's syndrome. METHODS--The study was multicentre (n = 3), double blind and placebo controlled. Sixty three patients who had eight or more vasospastic attacks per week were enrolled. After a one week run-in period, all patients received either iloprost or placebo treatment to a maximum tolerated dose of 150 micrograms twice a day for 10 days. Diary cards assessed the duration and severity of the vasospastic attacks. Side effects were monitored by direct questioning. A global assessment of treatment efficacy was made by the patient at the end of treatment and two weeks later. RESULTS--Patient opinion tended to favour iloprost at the end of the 10 day treatment phase (p = 0.09) and this was significant at day 24 (the follow up visit) (p = 0.011). Although the duration and severity of attacks tended to decrease in the iloprost treated group, these results tended not to reach statistical significance (for severity p = 0.06 at end of treatment, p = 0.09 on day 24). CONCLUSION--Iloprost administered intravenously has been shown to be of benefit in the treatment of the Raynaud's syndrome associated with systemic sclerosis, but this route of administration is inconvenient. This study evaluated the use of iloprost administered orally to patients with Raynaud's syndrome. Patient documented improvement was significantly improved by iloprost. Diary card analysis showed a trend in favour of iloprost, but these results did not reach statistical significance.

Full text

PDF
197

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acute severe asthma. Lancet. 1981 Feb 7;1(8215):313–314. [PubMed] [Google Scholar]
  2. Belch J. J., Greer I., McLaren M., Saniabadi A. R., Miller S., Sturrock R. D., Forbes C. D. The effects of intravenous ZK36-374, a stable prostacyclin analogue, on normal volunteers. Prostaglandins. 1984 Jul;28(1):67–77. doi: 10.1016/0090-6980(84)90114-x. [DOI] [PubMed] [Google Scholar]
  3. Belch J. J. The phenomenon, syndrome and disease of Maurice Raynaud. Br J Rheumatol. 1990 Jun;29(3):162–165. doi: 10.1093/rheumatology/29.3.162. [DOI] [PubMed] [Google Scholar]
  4. Dowd P. M., Kirby J. D., Holborow E. J., Cooke E. D., Bowcock S. A. Detection of immune complexes in systemic sclerosis and Raynaud's phenomenon. Br J Dermatol. 1981 Aug;105(2):179–188. doi: 10.1111/j.1365-2133.1981.tb01203.x. [DOI] [PubMed] [Google Scholar]
  5. Dowd P. M., Kovacs I. B., Bland C. J., Kirby J. D. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Br Med J (Clin Res Ed) 1981 Aug 1;283(6287):350–350. doi: 10.1136/bmj.283.6287.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Rademaker M., Cooke E. D., Almond N. E., Beacham J. A., Smith R. E., Mant T. G., Kirby J. D. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ. 1989 Mar 4;298(6673):561–564. doi: 10.1136/bmj.298.6673.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Rodeheffer R. J., Rommer J. A., Wigley F., Smith C. R. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med. 1983 Apr 14;308(15):880–883. doi: 10.1056/NEJM198304143081507. [DOI] [PubMed] [Google Scholar]
  8. Torley H. I., Madhok R., Capell H. A., Brouwer R. M., Maddison P. J., Black C. M., Englert H., Dormandy J. A., Watson H. R. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis. 1991 Nov;50(11):800–804. doi: 10.1136/ard.50.11.800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Utsunomiya T., Krausz M. M., Valeri C. R., Shepro D., Hechtman H. B. Treatment of pulmonary embolism with prostacyclin. Surgery. 1980 Jul;88(1):25–30. [PubMed] [Google Scholar]
  10. Wigley F. M., Seibold J. R., Wise R. A., McCloskey D. A., Dole W. P. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992 Sep;19(9):1407–1414. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES